mooie uitleg 2-73:
Anavex’s lead asset ANAVEX®2-73 is currently undergoing a Phase 2b/3 study in Alzheimer’s disease. The enrollment was 80% complete, and full enrollment of 450 patients is expected in early 2021, the company announced in late December.
ANAVEX 2-73 is based on oxidation and nitration causing Alzheimer’s. Other drug companies have instead focused on the cause being amyloid. They have misdiagnosed the cause while we believe Anavex has the correct approach.
Anti-amyloid and anti-tau drugs have proven to only slightly slow down the progression of Alzheimer’s disease. The prevention or removal of either has shown little effect on the progression of the disease.
Inflammation, tau, and amyloid all add to oxidative stress but are themselves the products of this stress. The key then is not only to inhibit oxidative stress (which only moderately slows down the progression of the disease over time), but to remove compounds that are causing oxidation and nitration, and reverse part of the damage that they are doing to the brain.
Oxidation and nitration also likely play a role in Parkinson’s Disease Dementia and Rett syndrome. This is why we believe Anavex 2-73 is the most promising drug being developed today.